| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 240 | 1,214 | 3,032 | 2,380 |
| Cost of revenue | -11 | - | - | - |
| Research and development | 151,463 | 97,509 | 118,645 | 195,178 |
| Cost of revenue | - | 11 | - | 50 |
| Selling, general and administrative | 22,231 | 22,283 | 23,944 | 25,744 |
| Restructuring, long-lived assets impairment and related charges, net | 0 | -172 | -10 | 12,712 |
| Total operating expenses | 173,683 | 119,631 | 142,579 | 233,684 |
| Loss from operations | -173,443 | -118,417 | -139,547 | -231,304 |
| Change in fair value of equity investments | 1,335 | -3,382 | 6,382 | 1,130 |
| Interest income | 9,363 | 10,785 | 12,288 | 17,527 |
| Other expense, net | -228 | 226 | -72 | -893 |
| Total other income | 10,470 | 7,629 | 18,598 | 17,764 |
| Loss before (provision for) benefit from income taxes | -162,973 | -110,788 | -120,949 | -213,540 |
| (provision for) benefit from income taxes | 168 | 170 | 16 | 177 |
| Net loss | - | - | - | -213,717 |
| Net loss | -163,141 | -110,958 | -120,965 | -213,717 |
| Net loss per share, basic (in usd per share) | -1.17 | -0.8 | -0.88 | -1.56 |
| Net loss per share, diluted (in usd per share) | -1.17 | -0.8 | -0.88 | -1.56 |
| Weighted-average shares outstanding, basic (in shares) | 138,930,173 | 138,447,469 | 137,468,900 | 136,653,753 |
| Weighted-average shares outstanding, diluted (in shares) | 138,930,173 | 138,447,469 | 137,468,900 | 136,653,753 |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)